Takeaway

• Apalutamide improved radiographic PFS (r-PFS) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).

Why this matters

• Because mCRPC is driven by activated androgen receptors and elevated intratumoral androgens, patients may benefit from an androgen annihilation strategy using apalutamide, which targets both pathways.

Study design

• Phase 3 ACIS trial: 982...